Fate Therapeutics (FATE) Operating Expenses (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Operating Expenses data on file, last reported at $34.3 million in Q1 2026.

• Quarterly Operating Expenses fell 20.07% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.7 million (down 31.84% YoY) and the FY2025 annual result came in at $154.4 million, down 31.07% from the prior year.
• Operating Expenses declined to $34.3 million in Q1 2026, from $36.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $108.8 million in Q4 2022 to a low of $34.3 million in Q1 2026.
• A 5-year average of $63.0 million and a median of $53.2 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 68.89% — and 2023, when it sank 54.26%.
• Tracing FATE's Operating Expenses over 5 years: stood at $108.8 million in 2022, then slumped by 54.26% to $49.8 million in 2023, then grew by 27.85% to $63.6 million in 2024, then slumped by 43.26% to $36.1 million in 2025, then dropped by 4.96% to $34.3 million in 2026.
• The last three Operating Expenses figures came in at $34.3 million (Q1 2026), $36.1 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.